Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains
- PMID: 1937767
- PMCID: PMC258999
- DOI: 10.1128/iai.59.11.4075-4083.1991
Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains
Abstract
The development of a small-animal model to test the protective efficacy and immunogenicity of a vaccine strain against shigellosis would greatly facilitate the evaluation of potential vaccine candidates. In guinea pigs, the ability of shigellae to invade and multiply within the corneal epithelium, causing keratoconjunctivitis, closely mimics the invasion process in the intestinal epithelium (B. Sereny, Acta Microbiol. Acad. Sci. Hung. 4:367-376, 1957). The serum response of animals recovering from a Shigella keratoconjunctival infection was determined and found to be consistent with that shown by convalescent humans and primates. This model was used to test the efficacy of two vaccine candidates, and the immune response of the guinea pigs to the vaccine strains was examined. Both vaccine strains demonstrated significant protection against challenge by homologous virulent Shigella strains, and the results were comparable with results obtained in trials with monkeys. The guinea pig model also provides a rapid and inexpensive means of evaluating different immunization regimens as well as of testing other variables such as length of protection against disease.
Similar articles
-
Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.Vaccine. 2006 May 1;24(18):3727-34. doi: 10.1016/j.vaccine.2005.07.013. Epub 2005 Jul 22. Vaccine. 2006. PMID: 16169130
-
Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.Infect Immun. 1996 Jan;64(1):23-7. doi: 10.1128/iai.64.1.23-27.1996. Infect Immun. 1996. PMID: 8557344 Free PMC article.
-
Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.Infect Immun. 2001 May;69(5):3150-8. doi: 10.1128/IAI.69.5.3150-3158.2001. Infect Immun. 2001. PMID: 11292735 Free PMC article.
-
Development of an auxotrophic oral live Shigella flexneri vaccine.Vaccine. 1988 Apr;6(2):146-50. doi: 10.1016/s0264-410x(88)80018-5. Vaccine. 1988. PMID: 2838986 Review.
-
Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.Biologicals. 1995 Jun;23(2):125-34. doi: 10.1006/biol.1995.0023. Biologicals. 1995. PMID: 7546655 Review.
Cited by
-
Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4. Infect Immun. 2014. PMID: 24595138 Free PMC article.
-
Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.Infect Immun. 1997 Jun;65(6):2112-8. doi: 10.1128/iai.65.6.2112-2118.1997. Infect Immun. 1997. PMID: 9169740 Free PMC article.
-
The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence.Gut Microbes. 2017 Jul 4;8(4):335-350. doi: 10.1080/19490976.2017.1293225. Epub 2017 Feb 13. Gut Microbes. 2017. PMID: 28277944 Free PMC article.
-
Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S580-S590. doi: 10.1093/cid/ciz892. Clin Infect Dis. 2019. PMID: 31816068 Free PMC article.
-
Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.Infect Immun. 1994 Feb;62(2):412-20. doi: 10.1128/iai.62.2.412-420.1994. Infect Immun. 1994. PMID: 7507892 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources